The constitutive mobilization of bone marrow–repopulating cells into the peripheral blood in idiopathic myelofibrosis

Mingjiang Xu, Edward Bruno, Joseph Chao, Hongyu Ni, Valerie Lindgren, Rafael Nunez, Nadim Mahmud, Guido Finazzi, Steven M. Fruchtman, Uday Popat, Enli Liu, Josef T. Prchal, Damiano Rondelli, Giovanni Barosi, and Ronald Hoffman

Idiopathic myelofibrosis (IM) is characterized by the constitutive mobilization of CD34+ cells. IM peripheral blood (PB) CD34+ cells had a reduced cloning efficiency and a lower frequency of cobblestone areas compared with normal granulocyte colony-stimulating factor (G-CSF)–mobilized PB CD34+ cells. IM CD34+ cells engrafted nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, demonstrating that they contain bone marrow (BM)–repopulating cells. G-CSF–mobilized CD34+ cells produced multiple hematopoietic lineages within the NOD/SCID mice with a predominance of CD19+ cells. By contrast, IM CD34+ cells produced predominantly CD33+ cells, increased numbers of CD41+ cells, but fewer CD19+ cells. Transcriptional clonality assays of the engrafted human IM cells demonstrated their clonal origin. CD34+ cells from one patient isolated prior to leukemic transformation were capable of generating acute leukemia in NOD/SCID mice. The engrafted human cells exhibited the same abnormal karyotype as primary cells in a portion of the population. These findings demonstrate that BM-repopulating cells and more differentiated progenitor cells are constitutively mobilized into the PB in IM, and that their differentiation program is abnormal. In addition, the NOD/SCID model may be useful in gaining an understanding of the events occurring during the transition of IM to acute leukemia. (Blood. 2005;105: 1699-1705)

© 2005 by The American Society of Hematology

Introduction

Chronic idiopathic myelofibrosis (IM) is a hematological malignancy characterized by splenomegaly, a leukoerythroblastic blood picture, teardrop poikilocytosis (dacrocystosis), varying degrees of bone marrow (BM) fibrosis, and extramedullary hematopoiesis.1-4 IM is thought to originate at the level of the multipotent hematopoietic stem cell (HSC).1-4 The HSC defect results in a profound hyperplasia of morphologically abnormal megakaryocytes and clonal populations of monocytes, which have been shown to locally release fibrogenic growth factors, leading to BM fibrosis.5-7 Rare CD34+ HSC/hematopoietic progenitor cells (HPCs) circulate in the peripheral blood (PB) of healthy individuals.8,9 Increased numbers of CD34+ cells can be mobilized into the PB following the administration of a variety of cytokines and/or chemotherapeutic agents.9,11 Barosi et al recently demonstrated that the PB of IM patients contained 360 times more CD34+ cells than normal controls and 18 to 30 times more CD34+ cells than patients with other Philadelphia chromosome–negative (Ph−) myeloproliferative disorders (MPDs).12 In addition, the PB CD34+ cell number was further shown to be related to disease progression and to serve as a biomarker for disease activity.12 The number of assayable HPCs present in the PB of IM patients have also been shown to be increased.13-15 Therefore, IM represents a unique situation in which the numbers of CD34+ cells appearing in the PB are frequently markedly increased in the absence of extrinsic stimuli.

Although the CD34 antigen is expressed by both the HSC and HPC, the functional potential of the CD34+ cells in the PB of IM patients has not been well defined. In this report we have further phenotyped the CD34+ cells of IM patients and examined the multilineage differentiation potential of these cells, as well as their ability to repopulate immunodeficient mice. In addition, we have demonstrated the utility of this in vivo model to analyze the cellular and molecular events that occur during the transition of IM to acute leukemia.

Patients, materials, and methods

Patients and healthy control subjects

All human tissue samples were obtained after informed consent following the guidelines of the institutional review board of the University of Illinois College of Medicine. PB samples were obtained from: (1) healthy donors in steady-state hematopoiesis; (2) healthy donors mobilized with granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA) at 5 μg/kg/d subcutaneously; and (3) patients with IM or polycythemia vera (PV) who met the World Health Organization (WHO) diagnostic criteria for IM and PV,13-16 as well as patients with secondary myelofibrosis associated with pulmonary hypertension.17 None of the patients were receiving cytotoxic agents at the time of study and none had evidence of transformation to acute leukemia. The specific clinical characteristics of the patients whose CD34+ cells were examined for BM-repopulating potential are described in Table 1.

Supported by a grant from the Myeloproliferative Disorder Foundation.

Reprints: Ronald Hoffman, University of Illinois at Chicago Cancer Center, 900 South Ashland Ave, M/C 700, Chicago, IL 60607-7171; e-mail: rhoff@uic.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology
Table 1. Clinical characteristics of patients with IM

<table>
<thead>
<tr>
<th>Patient no. (sex)</th>
<th>Hgb, g/L</th>
<th>WBC, x 10^9/L</th>
<th>Platelet count, x 10^9/L</th>
<th>Spleen size, cm</th>
<th>% blasts in PB</th>
<th>RBC transfusion requirement</th>
<th>Severity of BM fibrosis</th>
<th>Transition to acute leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM-1 (F)</td>
<td>106</td>
<td>24.2</td>
<td>275</td>
<td>4</td>
<td>0</td>
<td>Yes</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>IM-2 (F)</td>
<td>86</td>
<td>33.7</td>
<td>95</td>
<td>20</td>
<td>0</td>
<td>Yes</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>IM-3 (F)</td>
<td>75</td>
<td>18.0</td>
<td>26</td>
<td>16</td>
<td>0</td>
<td>Yes</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>IM-4 (F)</td>
<td>140</td>
<td>60.3</td>
<td>356</td>
<td>NA*</td>
<td>0</td>
<td>No</td>
<td>3</td>
<td>Yes (5 wk)</td>
</tr>
</tbody>
</table>

*Not applicable; patient was splenectomized.

Purification of human PB CD34^+ cells

The PB was layered onto Ficoll-Hypaque (1.077 g/mL; Amersham Biosciences, Piscataway, NJ), and low-density mononuclear cells (MNCs) separated after centrifugation. A CD34^+ cell population was isolated using a magnetic activated cell sorting CD34^+ Isolation Kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions. The purity of the CD34^+ cell population was analyzed using a FACSCaliber Flow Cytometer (Becton Dickinson, Mountain View, CA). Cell fractions showing a CD34^+ cell purity of 85% or greater were used for subsequent experiments including HSC phenotyping, in vitro progenitor assays, and transplantation into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

Phenotypic analysis of CD34^+ cells

Separate aliquots of isolated CD34^+ or MNCs were double stained with anti-CD34 and a panel of monoclonal antibodies (Abs) against c-kit, CD38, SCF, IL-3, and IL-6, and then analyzed flow cytometrically using a FACSCalibur. The percentage of CD34^+ cells expressing c-kit, CD38, SCF, IL-3, and IL-6, but not CD38, was then determined by flow cytometric analysis.

Cell-cycle analysis of PB CD34^+ cells was performed by propidium iodide (PI) staining as described previously. Briefly, cells were fixed in 70% ethanol; to avoid the formation of aggregates, the cell suspension was added dropwise onto 70% ethanol while vortexing and then kept on ice for 20 minutes. After twice washing with phosphate-buffered saline (PBS), cells were resuspended in PI, 0.138 mM NaCl at 4°C, and the DNA content analyzed with a FACSCalibur. Data files containing forward- and side-scatter peak signals as well as width and areas of the PI signal were collected. Doubled events were excluded by gating on the PI signal-width channel.

 Colony-forming cell and cobblestone area–forming cell assays

CD34^+ cells were incubated at a concentration of 500 cells/mL of culture mixture. One milliliter of culture mixture containing 500 cells, 0.9% methylcellulose, 30% fetal bovine serum (FBS), 1% bovine serum albumin (BSA), 0.05 mM 2-mercaptoethanol (2-ME; StemCell Technologies, Vancouver, Canada), and a cytokine cocktail containing stem cell factor (SCF; 100 ng/mL), interleukin-3 (IL-3; 100 ng/mL), IL-6 (100 ng/mL), GM-CSF (20 ng/mL), erythropoietin (EPO; 4 U/mL), and thrombopoietin (TPO; 100 ng/mL) (all from Amgen) was placed in 35-mm non–tissue culture dishes and incubated at 37°C in 5% CO2. All cultures were suspended in limiting dilution in Iscove modified Dulbecco medium (IMDM) containing 10% FBS, 10% CMC, 10% IL-3, and 10% IL-6. The cells were then incubated at 37°C in 5% CO2 with half of the incubating volume replaced with fresh media containing the same cytokine cocktail on a weekly basis. After 5 weeks of culture, the number of cobblestone areas was enumerated with an inverted microscope at days 12 to 14 of culture, according to previously published criteria.

NOD/SCID repopulating assay

NOD/LtSz-scid/scid (NOD/SCID) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in microisolators under specific pathogen-free conditions at the Biologic Resources Laboratory at the University of Illinois at Chicago. To optimize human cell engraftment, 7- to 8-week-old female NOD/SCID mice recipients received a series of pretreatments consisting of: (1) a sublethal dose of whole-body irradiation of 350 cGy with a cobalt radiation source; (2) intraperitoneal injections of 200 µg/mouse TM-B1 (BD Biosciences Pharmingen), a monoclonal antibody (mAb) directed against the murine IL-2Rα to eliminate remaining natural killer (NK) activity after irradiation; and (3) alternate-day intraperitoneal injections of 10 ng of recombinant human (Rhu) SCF, 6 µg of RhuGM-CSF, and 6 µg of RhuIL-3 per injection, for the first 10 days after transplantation.

For analysis of human cells in murine tissues, cell suspensions were prepared and injected into the tail veins of NOD/SCID mice at a dose of 0.5 to 3 x 10^6 cells/mouse in 0.5 mL PBS. In 2 cases, CD34^+ cells obtained from the flow-through of the CD34 selection columns were collected and injected intravenously at 15 to 30 x 10^6 cells/mouse. Nine to 16 weeks after human cell transplantation, the mice were killed and the PB, spleen, femur, and tibia were harvested for analysis. From these organs, cell suspensions were prepared, the red blood cells (RBCs) were treated with a lysis buffer (Sigma Chemical), and cell numbers and viability determined.

For analysis of human cells in murine tissues, cell suspensions were preincubated for 30 minutes at 4°C in PBS containing 0.1% BSA, 20% mouse serum, and 20% human serum. Separate cell aliquots were then incubated for 30 minutes at 4°C with a panel of mAbs against the following human markers conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin (APC): CD34, CD45, CD19, CD41a, immunoglobulin M (IgM), CD38, CD56, and CD3 (Becton Dickinson, San Jose, CA). A separate cell aliquot was stained with isotype-matched mAbs labeled with the same fluorochromes to establish the levels of non-specific immunofluorescence. After washing, 2 µg/mL PI was then added to eliminate dead (PI^+ ) cells from the analysis. The samples were then analyzed flow cytometrically using a FACSVerse. Routinely, 30,000 events were acquired per sample. The lack of cross-reactivity of human-specific antibodies with mouse cells was confirmed in every experiment by staining BM cells from an irradiated control mouse that did not receive a transplant. The percentage of human cells in the recipient was calculated as the number of human CD45^+ cells/the number of PI^+ cells x 100. Engraftment of human cells was defined by the presence of at least 0.1% nucleated cells expressing CD45 over the background fluorescence.

Immunohistochemical staining

Formalin-fixed and paraffin-embedded sections of tibiae from the recipient mice were stained with May-Grunwald-Giemsa. For immunohistochemical staining, the tissue sections were deparaffinized in xylene and hydrated in graded alcohol. The sections were then stained with a monoclonal mouse anti-human CD34 antibody (CD34QB10; DakoCytomation, Carpente-
ria, CA). Staining was performed on a DakoCytomation Histostainer using a streptavidin/horseradish peroxidase detection kit with the chromogen 3,3’-diaminobenzidine tetrahydrochloride (DAB). All staining procedures were performed utilizing an isotypic antibody as a negative control. The sections were examined under 200 x magnification using a Splan 20 objective lens with a numerical aperture of 0.46 on an Olympus BH-2 light microscope.
Transcriptional clonality assays

The genotypes for 5 X-chromosome exonic polymorphisms (MPP1, IDS, G6PD, BTK, and FHL1) of the 3 IM females were determined by real-time polymerase chain reaction (PCR) using commercial ABI TaqMan probes (Applied Biosystems, Foster City, CA).22 To examine the clonal origin of the human IM hematopoietic cells engrafted in NOD/SCID mice, RNA was extracted from human CD33+ cells purified from the femurs of these mice utilizing Miltenyi cell selection devices (Miltenyi Biotec). Transcriptional clonality assays were then performed using single-strand conformation polymorphism (SSCP) analysis as previously described.23

Cytogenetic analysis

Cytogenetic analysis was performed on the BM of patient IM-4 at the time of leukemic transformation (May 2003) and 1 year prior to that time. The human CD45+ cells isolated from the mice that received transplants of PB CD34+ cells obtained from patient IM-4 (5 weeks prior to the leukemia transformation) utilizing Miltenyi cell-selection devices were also analyzed. Cells were cultured for approximately 24 hours in the absence of mitogens. Chromosome preparation and banding were performed as previously described.23 An attempt was made to analyze at least 20 metaphases. The description of karyotypes follows the recommendations of the International System for Human Cytogenetic Nomenclature.24

Statistical analysis

Data points are expressed as the mean ± standard error of the mean (SEM). Differences between percentages of cells expressing a particular cellular phenotype were calculated using the Wilcoxon test, whereas differences between other variables were compared using either a Student t test or analysis of variance (ANOVA).

Results

Phenotypic analysis of CD34+ cells mobilized into the PB of IM

Previously, a greater number of CD34+ cells have been reported to circulate in the PB of patients with IM compared with healthy controls.12 We compared the percentage of CD34+ cells within the PB MNCs of patients with IM, healthy donors mobilized with G-CSF, healthy individuals, and patients with secondary myelofibrosis. As shown in Figure 1, the percentage of CD34+ cells within the PB MNC fraction from both patients with IM and healthy donors mobilized with G-CSF were dramatically elevated with a mean ± SEM of 8.34 ± 2.47% (P < .001), and 1.06 ± 0.42% (P < .01), respectively, compared with healthy volunteers (0.27 ± 0.20%). When 3 patients with secondary myelofibrosis associated with pulmonary hypertension were similarly studied, the percentage of CD34+ cells within the MNC fraction was not increased. However, a greater percentage of the cells within the MNC fraction in patients with PV were CD34+ than within that fraction in healthy controls (P < .05), albeit not to the same degree as that observed in IM. It is important to note the relative degree of CD34+ cell mobilization in IM was dramatically greater compared with G-CSF–mobilized donors (P < .01) and PV patients. These findings suggest IM is unique in that the CD34+ cells are preferentially mobilized into the PB.

CD34+ cells in IM PB were further characterized by mAb staining and flow cytometric analysis. Two-color staining and fluorescence-activated cell-sorting (FACS) analysis were performed on preisolated PB CD34+ cells from healthy volunteers or patients with IM. In some cases, IM PB MNCs were used directly for phenotypic analysis. As can be seen in Table 2, the fraction of IM PB CD34+ cells expressing CD117 (c-kit), CD38, CD90, and CD33 are significantly different than that of healthy volunteers. A greater percentage of IM PB than normal PB CD34+ cells were c-kit+, CD38+, and CD90+ (Table 2), suggesting that the CD34+ cells in the PB of IM patients might represent a more primitive population of HPCs than that which normally circulates in the PB. In addition, the expression of the myeloid lineage marker CD33 was shown to be significantly increased in IM PB CD34+ cells.

It has been reported that virtually all of the PB CD34+ cells mobilized by G-CSF are noncycling quiescent cells.22-24 We therefore performed cell-cycle analysis using flow cytometry to determine the percentage of quiescent IM PB CD34+ cells. Similar to normal PB CD34+ cells and G-CSF mobilized CD34+ cells, more than 98% of the IM CD34+ cells resided within the G0/G1 phase (data not shown).

Table 2. Phenotype of CD34+ cells in normal and IM PB

<table>
<thead>
<tr>
<th>Cell surface antigens</th>
<th>Mean normal PB ± SD, %*</th>
<th>Mean IM PB ± SD, %†</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD117 (c-kit)</td>
<td>16.0 ± 7.3</td>
<td>40.8 ± 15.1‡</td>
</tr>
<tr>
<td>CD90 (Thy-1)</td>
<td>23.9 ± 4.6</td>
<td>43.5 ± 5.8‡</td>
</tr>
<tr>
<td>CD38 (Negative)</td>
<td>0.6 ± 0.4</td>
<td>4.7 ± 3.6‡</td>
</tr>
<tr>
<td>CD33</td>
<td>33.0 ± 5.8</td>
<td>57.2 ± 13.5‡</td>
</tr>
</tbody>
</table>

* †n = 8.
‡ P < .05.

IM PB CD34+ cells have decreased cloning efficiency in vitro

In order to examine the differentiation potential of IM HSCs/HPCs, the number and type of HPCs assayed from PB CD34+ cells isolated from 6 healthy volunteers, 4 healthy donors mobilized with G-CSF, and 7 patients with IM were enumerated. As shown in Figure 2, about 60% of the colonies formed by normal PB CD34+ cells were derived from burst-forming unit–erythroid (BFU-E), while both IM and G-CSF–mobilized CD34+ cells generated predominantly CFU-GM–derived colonies (~80%). More importantly, the cloning efficiency of IM CD34+ cells was significantly lower than that of normal PB CD34+ cells (P < .01). The cloning efficiency of IM CD34+ cells and CD34+ cells isolated from G-CSF–mobilized PB were, however, similar (P > .05), as was the distribution of the colony types formed (Figure 3). Since there are greater numbers of CD34+ cells in the PB of IM patients, the absolute number of assayable HPCs are clearly increased in
patients with IM compared with healthy individuals or even G-CSF–mobilized healthy volunteers.

We next assessed the ability of IM PB MNCs and CD34+ cells to form CAFCs in a stromal cell–based culture system after 5 weeks of incubation. The frequency of CAFCs has been previously used as an in vitro surrogate assay for human HSCs.19 As can be seen in Table 3, the frequency of CAFCs in IM PB MNCs was shown to be higher than that observed in G-CSF–mobilized healthy donors, suggesting that IM is also associated with the mobilization of greater numbers of more primitive HPCs (CAFCs) than G-CSF mobilization. However, the frequency of CAFCs within the CD34+ cells was 3-fold lower in IM PB, compared with normal PB and G-CSF–mobilized PB (Table 4). These findings suggest that the preferential mobilization of HSCs/HPCs in IM is also accompanied by abnormalities in CD34+ cell function.

**IM PB CD34+ cells contain NOD/SCID repopulating cells**

Although there is a significant mobilization of CD34+ cells into the PB in IM, one cannot be certain, at present, if these PB CD34+ cells were analyzed by flow cytometry at 9 to 15 weeks after transplantation.

Using transcriptional clonality assays,22 we analyzed the clonal origin of those hematopoietic cells which engrafted into the NOD/SCID mice. As shown in the Figure 4, these mice was derived from the same clone as the human IM cells. This finding demonstrated that the human hematopoiesis present in these mice was derived from the same clone as the human IM cells.

**Development of leukemia in the mice receiving IM PB CD34+ cells**

Patient IM-4 represented a unique opportunity to observe the evolution of IM to acute leukemia. Although the PB cells from this patient were harvested at a time when the patient’s disease

<table>
<thead>
<tr>
<th>Source of PB MNCs</th>
<th>No. studied</th>
<th>CAFC frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal PB</td>
<td>2</td>
<td>1 in 206 (157-270)</td>
</tr>
<tr>
<td>Mobilized PB</td>
<td>2</td>
<td>1 in 186 (162-212)</td>
</tr>
<tr>
<td>IM PB</td>
<td>3</td>
<td>1 in 746 (477-955)</td>
</tr>
</tbody>
</table>

**Table 4. Frequency of CAFCs in PB CD34+ cells from healthy volunteers, healthy G-CSF-mobilized donors, and patients with IM**

**Figure 3. Multilineage engraftment of NOD/SCID mice.** (A) Analysis of myelopoiesis, B lymphopoiesis, and megakaryopoiesis in the BM of the NOD/SCID mice that received transplants of either normal G-CSF–mobilized PB (n = 3) or IM PB (n = 3) CD34+ cells. Overall distribution of myeloid (CD33+) lineages, B-lymphoid (CD19+) lineages, progenitor cells (CD34+), and megakaryocytes (CD41+) among human cells (CD45+) were is shown as the mean ± SD. (B) Representative flow cytometric analysis of BM from mice that received transplants of PB CD34+ cells from a G-CSF–mobilized volunteer (top row) or a patient with IM (bottom row). BM cells were analyzed by flow cytometry at 9 to 15 weeks after transplantation.

Table 3. Frequency of CAFCs in PB MNCs from healthy G-CSF-mobilized donors and patients with IM

<table>
<thead>
<tr>
<th>Source of PB MNCs</th>
<th>No. studied</th>
<th>CAFC frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobilized PB</td>
<td>2</td>
<td>1 in 386</td>
</tr>
<tr>
<td>IM PB</td>
<td>3</td>
<td>1 in 245</td>
</tr>
</tbody>
</table>

**Figure 2. Cloning efficiency of normal PB (NPB; n = 6), G-CSF–mobilized PB (n = 4) and IM PB (n = 7) CD34+ cells.** The number of CFUs is the sum of the number of BFU-E (○), CFU-GM (●) and BFU-E–granulocyte erythrocyte monocyte macrophage (GEMM; □)–derived colonies cloned per 2000 CD34+ cells plated. Values are expressed as the mean ± SD. Difference in CFU formation between normal PB and IM PB was statistically significant (P < .005).
Table 5. IM CD34⁺ cells contain SCID-repopulating cells

<table>
<thead>
<tr>
<th>Donor no.</th>
<th>No. of cells transplanted</th>
<th>Frequency of engraftment</th>
<th>Human CD45⁺ cells in BM, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-CSF–mobilized PB CD34⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-1</td>
<td>$1.9 \times 10^6$</td>
<td>1/1</td>
<td>12.4</td>
</tr>
<tr>
<td>N-2</td>
<td>$2.5 \times 10^6$</td>
<td>1/1</td>
<td>21.5</td>
</tr>
<tr>
<td>N-3</td>
<td>$0.5 \times 10^6$</td>
<td>1/1</td>
<td>0.3</td>
</tr>
<tr>
<td>IM PB CD34⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM-1</td>
<td>$3.0 \times 10^6$</td>
<td>6/6</td>
<td>1.9</td>
</tr>
<tr>
<td>IM-2</td>
<td>$1.2 \times 10^6$</td>
<td>2/2</td>
<td>0.7</td>
</tr>
<tr>
<td>IM-3</td>
<td>$0.5 \times 10^6$</td>
<td>2/2</td>
<td>1.5</td>
</tr>
<tr>
<td>IM-4</td>
<td>$3.0 \times 10^6$</td>
<td>3/3</td>
<td>83.0</td>
</tr>
</tbody>
</table>

Figure 4. Transcriptional clonality assay of G6PD in human CD33⁺ cells isolated from mice that received transplants of IM PB CD34⁺ cells. Lanes 1-3 show clonal expression of G6PD in human CD33⁺ cells from 3 individual mice, each given transplants of CD34⁺ cells from a different female IM patient: IM-1 (lane 1), IM-2 (lane 2) and IM-3 (lane 3). Lane 4 shows negative control. Lane 5 shows positive control for clonal expression of G6PD on T allele. Lane 6 shows positive control for clonal expression of G6PD on C allele. Lane 7 shows positive control for polyclonal expression of G6PD on both T and C alleles.

Figure 5. Analysis of hematopoietic tissues obtained from NOD/SCID mice receiving transplants of CD34⁺ cells from patient IM-4. (A) Representative flow cytometric analysis of BM (left column), spleen (middle column), and PB (right column) from mice that received transplants of PB CD34⁺ cells isolated from patient IM-4. Cells were analyzed by flow cytometry at 12 weeks after transplantation. (B) May-Grunwald-Giemsa staining (×200) and (C) anti-CD34 immunochromatic staining (×200) of a section of tibia from the mouse that received a transplant of cells isolated from patient IM-4.

Discussion

The CD34 surface antigen has served as a means to identify and separate HSCs and HPCs from their more differentiated progeny. CD34 is present on approximately 0.05% of nucleated circulating cells. By quantitating the absolute number of CD34⁺ cells in the PB of a large, well-defined population of patients, Barosi et al have shown that the PB of IM patients contained 360 times more CD34⁺ cells than healthy controls, and 18 to 30 times more CD34⁺ cells than patients with other Ph⁻ MPDs. The CD34⁺ cell number was further shown to be related to disease progression and to serve as a biomarker for disease activity.

In this study, we characterized the IM PB CD34⁺ cells by an array of phenotypic and functional assays. We found that IM PB CD34⁺ cells contained a phenotypically more primitive population of HPCs than that of normal PB, with a greater percentage of the IM PB CD34⁺ cells exhibiting a c-kit⁺, CD90⁺, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype. Most human primitive hematopoietic cells with high potential for self-renewal and multilineage differentiation have been reported to express high levels of c-kit or CD90, and CD38⁻ phenotype.

Interestingly, despite containing a phenotypically more primitive population of HPCs, IM PB CD34⁺ cells displayed a significantly lower frequency of colony-forming cells (CFCs) and CAFCs compared with normal controls. This reduced cloning efficiency of IM CD34⁺ cells is either a consequence of the mobilization process or a function of a malignant transformation event that characterizes these cells. A resolution of this question will require additional studies using CD34⁺ cells isolated from larger numbers of IM patients.

These findings also suggest that the preferential mobilization of CD34⁺ cells in IM is accompanied by abnormalities in cell function. This discordance between phenotype and function is reminiscent of the behavior of CD34⁺ cells isolated from patients...
with myelodysplasia and acute myeloid leukemia, in which increased numbers of PB CD34⁺ cells have also been associated with reduced CD34⁺ cell cloning efficiency.²⁹,³⁰

The use of immunodeficient mice as hosts of human HSC transplantsations has provided powerful models for both normal and abnormal human hematopoiesis.¹⁹,²¹,³¹-³⁷ Subfractionation of the input cells coupled with time-course studies of the number and types of the mature progeny produced has revealed the presence of a hierarchy of primitive transplantable progenitors that produce different spectra of progeny for varying, but predictable periods.³¹-³⁷ In this study, we have demonstrated for the first time that NOD/SCID BM-repopulating cells exist within the PB CD34⁺ cells of patients with IM. More important, the differentiation program of the IM PB CD34⁺ cells differ from that of normal CD34⁺ cells mobilized into the PB with G-CSF. These IM CD34⁺ cells have the unique ability to generate a greater fraction of CD34⁺, CD33⁺, and CD41⁺ cells. Similarly, Thanopoulou et al have reported that lineage cells from myelodysplasia patients repopulate NOD/SCID-β2m−/− mice and produce an abnormal differentiation pattern.³³ Thus, our data demonstrate the potential of the NOD/SCID model for future investigations of IM.

IM is believed to originate at the level of the HSCs, resulting in a profound hyperplasia of morphologically abnormal megakaryocytes and clonal populations of monocytes.¹³-¹⁴ It would therefore be important to know if the engrafted human cells in the NOD/SCID mice are derived from the malignant clone. Using both transcriptional clonality assays and cytogenetic studies, we have demonstrated that the engrafted human hematopoietic cells in the mice given transplants of PB CD34⁺ cells from each IM patient were clonal in origin, indicating that they are derived from the abnormal clone of the patient. Although it has been reported that NOD/SCID mice have been repopulated with both normal and leukemic human cells after transplantation of cells from patients with chronic myeloid leukemia, the vast majority (> 90%) of human progenitors present in the BM of the NOD/SCID mice were Ph⁺ by cytogenetic analysis.³⁴ Preliminary studies using marker chromosome abnormalities or restriction fragment length polymorphisms have documented that about 80% of circulating CD34⁺ cells in a patient with IM are clonal.³⁰

One of the hallmarks of IM is the inevitable progression of the disease to acute leukemia.¹³-¹⁴ In this study, we also observed this leukemic transformation in vivo in NOD/SCID mice given transplants of stable-state IM PB CD34⁺ cells. The IM patient from whom the sample was derived eventually underwent acute leukemia transformation. This ability to observe the evolution of leukemia from IM in vivo has not to our knowledge been previously reported. Although such events would likely be rare, this model provides an in vivo system in which to analyze the events in individual patients that play a role in the progression of IM to acute leukemia. In addition, IM-engrafted NOD/SCID mice should offer new opportunities for developing and testing novel therapeutic agents for the treatment of IM.

Acknowledgment

We would like to thank Manuel B. Borse for his assistance.

References


Table 6. Cytogenetic abnormalities in cells from patient IM-4 engrafted in NOD/SCID mice

<table>
<thead>
<tr>
<th>Source</th>
<th>Distribution</th>
<th>Karyotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM BM (May 2002)</td>
<td>25</td>
<td>45, XX, ins(1)(p13), add(3)(q11.2), del(5)(q15q33), – 10, – 12, add(16)p11.2, – 17, + 2mar*</td>
</tr>
<tr>
<td>20</td>
<td>46, XX, der(6)(l;1,6)(q25;p23)</td>
<td></td>
</tr>
<tr>
<td>Leukemic transformation BM (May 2003)</td>
<td>55</td>
<td>46, XX</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>45, XX, +inv dup(1)(p21p33), der(3)(l;3;16)(q11.2;p11.2), del(5)(q15q33), del(7)(q22), – 10, – 12, der(16)(l;16;17)(p11.2;q11.2), – 17, + 2mar*</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>46, XX, der(6)(l;1,6)(q25;p23)</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>46, XX</td>
</tr>
<tr>
<td>Engrafted human cells in NOD/SCID mice (December 2003)</td>
<td>13</td>
<td>45, XX, +inv dup(1)(p21p33), der(3)(l;3;16)(q11.2;p11.2), del(5)(q15q33), del(7)(q22), – 10, – 12, der(16)(l;16;17)(p11.2;q11.2), – 17, + 2mar*</td>
</tr>
<tr>
<td></td>
<td>87</td>
<td>42-44, XX, del(1)(p34.1), – 4, add(5)(p273), – 7, del(8)(q13), – 10, der(11)(l;74;11)(q27;q23), add(12)(q34.3), add(13)(q34), – 17, 7dup(17)(p11.2), + mar</td>
</tr>
</tbody>
</table>

*Apparent differences between these karyotypes, other than the deletion 7, are the result of differences in interpretation between 2 cytogenetic laboratories; the chromosomes are in fact the same. The dates represent the time of sample collection.


The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis

Mingjiang Xu, Edward Bruno, Joseph Chao, Hongyu Ni, Valerie Lindgren, Rafael Nunez, Nadim Mahmud, Guido Finazzi, Steven M. Fruchtman, Uday Popat, Enli Liu, Josef T. Prchal, Damiano Rondelli, Giovanni Barosi and Ronald Hoffman